These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26472735)

  • 21. Interphase fluorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. a study of 40 early-onset patients.
    Doneda L; Montillo M; Intropido L; Tedeschi A; Morra E; Larizza L
    Cancer Genet Cytogenet; 2003 Jan; 140(1):31-6. PubMed ID: 12550755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A large interstitial 11q deletion with isolated mild intellectual disability: review of the literature for genotype-phenotype correlation.
    Lallar M; Srivastava P; Phadke SR
    Clin Dysmorphol; 2018 Oct; 27(4):142-144. PubMed ID: 29847353
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
    Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
    Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival.
    Zenz T; Stilgenbauer S
    Leuk Lymphoma; 2009 Oct; 50(10):1559-61. PubMed ID: 19701850
    [No Abstract]   [Full Text] [Related]  

  • 25. Novel agents in chronic lymphocytic leukemia.
    Lamanna N; O'Brien S
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):137-145. PubMed ID: 27913472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
    Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia.
    Sarid N; Eshel R; Rothman R; Shpringer M; Perry C; Solar I; Dezorella N; Gepstein L; Canaani J; Naparstek E; Polliack A; Herishanu Y
    Eur J Haematol; 2012 Nov; 89(5):430-1. PubMed ID: 22816611
    [No Abstract]   [Full Text] [Related]  

  • 29. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
    Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
    Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of chronic lymphocytic leukaemia incidence in Germany and of patients ineligible for standard chemotherapy.
    Eisemann N; Schnoor M; Katalinic A
    Hematol Oncol; 2016 Jun; 34(2):93-101. PubMed ID: 25757806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia.
    Park TS; Cheong JW; Song J; Choi JR
    Leuk Res; 2009 Jul; 33(7):1001-4. PubMed ID: 19155067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
    Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
    Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
    Thompson PA; O'Brien SM; Xiao L; Wang X; Burger JA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG
    Cancer; 2016 Feb; 122(4):565-73. PubMed ID: 26588193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
    García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
    Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules.
    Dickinson JD; Gilmore J; Iqbal J; Sanger W; Lynch JC; Chan J; Bierman PJ; Joshi SS
    Leuk Lymphoma; 2006 Feb; 47(2):231-44. PubMed ID: 16321852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety profiles of novel agent therapies in CLL.
    Ahn IE; Davids MS
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):354-357. PubMed ID: 29222278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 23-year-old woman with 11q-chronic lymphocytic leukemia.
    Miguel CE; de Oliveira FM; Leite-Cueva SD; Rego EM; Falcão RP
    Med Oncol; 2011 Dec; 28(4):1534-6. PubMed ID: 20440658
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
    Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
    Owen C; Bence-Bruckler I; Chamakhi I; Toze C; Assaily W; Christofides A; Robinson S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):303-13. PubMed ID: 25937158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.